Browse > Article
http://dx.doi.org/10.4014/mbl.1608.08009

The Role of Complement in the Immunologic Microenvironment of Tumor Cells: Potential Therapeutic Targets  

Jo, Kyeong Beom (Department of Bioscience Education, King's College London)
Snape, Alison (Department of Bioscience Education, King's College London)
Publication Information
Microbiology and Biotechnology Letters / v.44, no.4, 2016 , pp. 420-431 More about this Journal
Abstract
The complement system comprises a set of essential molecules that bridge the innate and adaptive immune responses. Research has focused on how the complement system's destructive mechanism could potentially be harnessed for cancer treatment. However, cancer subverts the complement system to avoid immunosurveillance. In addition, a complement-triggered biological mechanism that contributes to cancer growth has been identified. Thus, drugs should be designed to homeostatically maintain a normal concentration of complement. This review explores three types of complement-related anti-cancer drugs: therapeutic antibodies, complement inhibitory drugs, and anti-complement regulatory drugs.
Keywords
Complement; immune system; tumour cells; immunosurveillance; inflammation; therapeutics;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Donin D, Jurianz K, Ziporen L, Schultz S. Kirschfink M, Fishelson Z. 2003. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. ExpImmunol. 131: 254-263.
2 Dougan M, Dranoff G. 2009. Immune therapy for cancer. Annual Rev. Immunol. 27: 83-117.   DOI
3 Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC. 2003. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer. Immunol. Immunother. 52: 638-642.   DOI
4 Ferlay J, SoerjomataramI, Ervik M, Dikshit R, Eser S, Mathers C, et al. 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Available from http://globocan.iarc.fr. Accessed December 2015.
5 Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. 2003. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40: 109-123.   DOI
6 Gasque P, Thomas A, Fontaine M, Morgan BP. 1996. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J. Neuroimmunol. 66: 29-40.   DOI
7 Gminski J, Mykala-Ciesla J, Machalski M, Drozdz M, Najda J. 1992. Immunoglobulins and complement components levels in patients with lung cancer. Rom. J. Intern. Med. 30: 39-44.
8 Swann JB, Smyth MJ. 2007. Immune surveillance of tumour. J. Clin. Invest. 117: 1137-1146.   DOI
9 Szebeni J. 2004. The complement system: Novel Roles in Health and Disease. Boston: Kluwer Academic Publishers. 4: 265-304.
10 Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177: 362-377.   DOI
11 Tegla CA, Cudrici C, Patel S, Trippe R, Rus V, Niculescu F. et al. 2011. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol. Res. 51: 45-60.   DOI
12 Vagas-Madrazo E, Lara-Ochoa F, Almagro JC. 1995. Canonical structure repertoire of the antigen-binding site of immunoglobulins suggests strong geometrical restrictions associated to the mechanism of immune recognition. J. Mol. Biol.254: 497-504.   DOI
13 Woodruff TM, Nandakumar KS, Tedesco F. 2011. Inhibiting the C5-C5a receptor axis. MolImmunol. 48: 1631-1642.
14 Janssen BJ, Halff EF, Lambris JD, Gros P. 2007. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 282: 29241-29247.   DOI
15 Ytting H, Jensenius JC, Christensen J, Thiel S, Nielsen HJ. 2004. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J. Gastroenterol. 39: 674-679.   DOI
16 Zipfel PF, Skerka C. 2009. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9: 729-740.   DOI
17 Gunn L, Ding C, Liu M, Ma Y, Qi C, Cai Y. et al. 2012. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J. Immunol. 189: 2985-2994.   DOI
18 Guo RF, Ward PA. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852.   DOI
19 Guo Y, Xu F, Lu T, Duan Z, Zhang Z. 2012. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38: 904-910.   DOI
20 Kempshall E, Thebault S, Morgan BP, Harris CL, Gallimore A. 2012. Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. Immunol. Cell Biol. 90: 869-871.   DOI
21 Kolev M, Towner L, Donev R. 2011. Complement in cancer and cancer immunotherapy. Arch. Immunol. Ther. Exp. (Warsz). 59: 407-419.   DOI
22 Kraus S, Fishelson Z. 2000. Cell densensitization by sublytic C5Bb-9 complexes and calcium ionophores depends on activatin of protein kinase C. Eur. J. Immunol. 30: 1272-1280.   DOI
23 Kraus S, Seger R, Fishelson Z. 2001. Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis. Clin. ExpImmunol. 123: 366-374.
24 Kraut EH, Sagone AL Jr. 1981. Alternative pathway of complement in multiple myeloma. Am. J. Hematol. 11: 335-345.   DOI
25 Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C. et al. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 1225-1235.   DOI
26 Kuraya M, Yefenof E, Klein G, Klein E. 1992. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis. Eur. J. Immunol., 22: 1871-1876.   DOI
27 Lucas SD, Karlsson-Parra A, Nilsson B, Grimelius L, Akerstrom G, Rastad J. et al.1996. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum. Pathol. 27: 1329-1335.   DOI
28 Maness PF, Orengo A. 1977. Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases. Oncology 34: 87-89.   DOI
29 Markiewski MM, Lambris JD. 2007. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171: 715-727.   DOI
30 Markiewski MM, Lambris JD. 2009. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 30: 286-292.   DOI
31 McConnell I, Klein G, Lint TF, Lachmann PJ. 1978. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur. J. Immunol. 8: 453-458.   DOI
32 Morgan BP, Harris CL. 2015. Complement, a target for therapy in inflammatory and degenerative disease. Nat. Rev. Drug Discov. 14: 857-877.   DOI
33 Niculescu F, Badea T, Rus H. 1999. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis. 142: 47-56.   DOI
34 Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME. 1988. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest. 81: 1122-1128.   DOI
35 Niculescu F, Rus H, Van Biesen T, Shin ML. 1997. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J. Immunol. 158: 4405-4412.
36 Niculescu F, Rus HG, Retegan M, Vlaicu R. 1992. Persistent complement activation on tumor cells in breast cancer. Am. J. Pathol. 140: 1039-1043.
37 Austin EB, Robins RA, Durrant LG, Price MR, Baldwin RW. 1989. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. J. Immunology 67: 525-530.
38 Bu X, Zheng Z, Wang C, Yu Y. 2007. Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells. Pathol. Res. Pract. 203: 163-167.   DOI
39 Bureeva S, Andia-Pravdivy J, Kaplun A. 2005. Drug design using the example of the complement system inhibitors' development. Drug Discov. Today 10: 1535-1542.   DOI
40 Cimino-Mathews A, Foote JB, Emens LA. 2015. Immune targeting in breast cancer. Oncology 29: 375-385.
41 Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.   DOI
42 Nishioka K, Kawamura K, Hirayama T, Kawashima T, Shimada K. 1976. The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann. N Y Acad. Sci. 276: 303-315.   DOI
43 Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly, DC, Wu Y-Q, DeAngelis RA. 2012. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14: 994-1004.   DOI
44 Pio R, Ajona D, Lambris JD. 2013. Complement inhibition: promising concept for cancer treatment. Semin. Immunol. 25: 54-64.   DOI
45 Ricklin D, Lambris JD. 2007. Complement-targeted therapeutics. Nat. Biotechnol. 25: 1265-1275.   DOI
46 Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. 2010. Cancer and the complement cascade. Molecul. Cancer Res. 8: 1453-1465.   DOI
47 Sahu A, Lambris JD. 2000. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 49: 133-148.   DOI
48 Sahu A, Morikis D, Lambris JD. 2003. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. MolImmunol. 39: 557-566.
49 Spiller OB, Criado-Garcia O, Rodriguez De Cordoba S, Morgan BP. 2000. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. ExpImmunol. 121: 234-241.
50 Spendlove L, Li L, Potter V, Christiansen D, Loveland BE, Durrant LG. 2000. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur. J. Immunol. 30: 2944-2953.   DOI
51 Davis AE, Lu F, Mejia P. 2010. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb. Haemost. 104: 886-893.   DOI
52 Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD. et al. 2012. Anaphylatoxin c5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 189: 4674-4683.   DOI